Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Dec 15, 2018 9:50pm

92 Views

Post# 29120662

RE:RE:CVD IN T2D

Jk, I didn't watch the video but saw the slides. It focuses on the SGLT2 inhibitors and GLP1-receptor agonist classes of drugs. They are the competition that apabetalone needs to beat. I've commented on them numerous times over the past few years. You should be familiar with these. If not, you've got some homework to do. BearDownAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload